Y-mAbs Therapeutics (NASDAQ:YMAB) Announces Earnings Results, Misses Estimates By $0.02 EPS

Y-mAbs Therapeutics (NASDAQ:YMAB) released its quarterly earnings data on Friday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02), RTT News reports. The business had revenue of $18.46 million during the quarter, compared to analysts’ expectations of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. During the same quarter in the previous year, the company posted ($0.18) EPS. Y-mAbs Therapeutics updated its FY 2024 guidance to EPS.

Y-mAbs Therapeutics Stock Down 0.5 %

NASDAQ YMAB opened at $15.48 on Friday. Y-mAbs Therapeutics has a fifty-two week low of $4.69 and a fifty-two week high of $20.90. The business has a fifty day moving average of $14.11 and a 200-day moving average of $13.16. The stock has a market cap of $689.94 million, a price-to-earnings ratio of -28.67 and a beta of 0.68.

Insider Activity at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 65,000 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $13.47, for a total value of $875,550.00. Following the completion of the transaction, the insider now owns 97,681 shares of the company’s stock, valued at approximately $1,315,763.07. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 65,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $13.47, for a total value of $875,550.00. Following the completion of the sale, the insider now directly owns 97,681 shares of the company’s stock, valued at approximately $1,315,763.07. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Joris Wilms sold 5,000 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the sale, the chief operating officer now owns 30,600 shares in the company, valued at $449,514. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 100,000 shares of company stock valued at $1,338,100 over the last quarter. Insiders own 22.50% of the company’s stock.

Analysts Set New Price Targets

YMAB has been the subject of a number of research analyst reports. Morgan Stanley cut their price target on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a report on Tuesday, August 13th. Canaccord Genuity Group reiterated a “buy” rating and set a $26.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Wedbush restated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Finally, BMO Capital Markets decreased their target price on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $21.14.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.